PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, May 6, 2021 at 4:30 PM Eastern Time to discuss its financial results and provide a business update for first quarter 2021.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.  The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Zokinvy^® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approved product.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). 

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:

Sri Ryali
Email: [email protected]
Phone: 1-650-272-6138

View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-first-quarter-2021-financial-results-and-business-update-on-thursday-may-6-2021-301280002.html

SOURCE Eiger BioPharmaceuticals, Inc.